TY - JOUR
T1 - NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT)
T2 - evaluation of a national guideline on management of neonatal catheter-related thrombosis
AU - Sol, Jeanine J
AU - van de Loo, Moniek
AU - Boerma, Marit
AU - Bergman, Klasien A
AU - Donker, Albertine E
AU - van der Hoeven, Mark A H B M
AU - Hulzebos, Christiaan V
AU - Knol, Ronny
AU - Djien Liem, K
AU - van Lingen, Richard A
AU - Lopriore, Enrico
AU - Suijker, Monique H
AU - Vijlbrief, Daniel C
AU - Visser, Remco
AU - Veening, Margreet A
AU - van Weissenbruch, Mirjam M
AU - van Ommen, C Heleen
N1 - Funding Information:
This trial is partly funded by an unrestricted grant of Daiichi Sankyo. Daiichi Sankyo has no role in the design of the study and the collection, analysis and interpretation of data, and in writing the manuscript.
Publisher Copyright:
© 2018 The Author(s).
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/2/23
Y1 - 2018/2/23
N2 - Background: In critically ill (preterm) neonates, central venous catheters (CVCs) are increasingly used for administration of medication or parenteral nutrition. A serious complication, however, is the development of catheter-related thrombosis (CVC-thrombosis), which may resolve by itself or cause severe complications. Due to lack of evidence, management of neonatal CVC-thrombosis varies among neonatal intensive care units (NICUs). In the Netherlands an expert-based national management guideline has been developed which is implemented in all 10 NICUs in 2014. Methods: The NEOCLOT study is a multicentre prospective observational cohort study, including 150 preterm and term infants (0-6 months) admitted to one of the 10 NICUs, developing CVC-thrombosis. Patient characteristics, thrombosis characteristics, risk factors, treatment strategies and outcome measures will be collected in a web-based database. Management of CVC-thrombosis will be performed as recommended in the protocol. Violations of the protocol will be noted. Primary outcome measures are a composite efficacy outcome consisting of death due to CVC-thrombosis and recurrent thrombosis, and a safety outcome consisting of the incidence of major bleedings during therapy. Secondary outcomes include individual components of primary efficacy outcome, clinically relevant non-major and minor bleedings and the frequency of risk factors, protocol variations, residual thrombosis and post thrombotic syndrome. Discussion: The NEOCLOT study will evaluate the efficacy and safety of the new, national, neonatal CVC-thrombosis guideline. Furthermore, risk factors as well as long-term consequences of CVC-thrombosis will be analysed.
AB - Background: In critically ill (preterm) neonates, central venous catheters (CVCs) are increasingly used for administration of medication or parenteral nutrition. A serious complication, however, is the development of catheter-related thrombosis (CVC-thrombosis), which may resolve by itself or cause severe complications. Due to lack of evidence, management of neonatal CVC-thrombosis varies among neonatal intensive care units (NICUs). In the Netherlands an expert-based national management guideline has been developed which is implemented in all 10 NICUs in 2014. Methods: The NEOCLOT study is a multicentre prospective observational cohort study, including 150 preterm and term infants (0-6 months) admitted to one of the 10 NICUs, developing CVC-thrombosis. Patient characteristics, thrombosis characteristics, risk factors, treatment strategies and outcome measures will be collected in a web-based database. Management of CVC-thrombosis will be performed as recommended in the protocol. Violations of the protocol will be noted. Primary outcome measures are a composite efficacy outcome consisting of death due to CVC-thrombosis and recurrent thrombosis, and a safety outcome consisting of the incidence of major bleedings during therapy. Secondary outcomes include individual components of primary efficacy outcome, clinically relevant non-major and minor bleedings and the frequency of risk factors, protocol variations, residual thrombosis and post thrombotic syndrome. Discussion: The NEOCLOT study will evaluate the efficacy and safety of the new, national, neonatal CVC-thrombosis guideline. Furthermore, risk factors as well as long-term consequences of CVC-thrombosis will be analysed.
KW - Antithrombotic therapy
KW - Catheter
KW - Neonate
KW - Observational
KW - Thrombosis
UR - http://www.scopus.com/inward/record.url?scp=85042400149&partnerID=8YFLogxK
U2 - 10.1186/s12887-018-1000-7
DO - 10.1186/s12887-018-1000-7
M3 - Article
C2 - 29475450
SN - 1471-2431
VL - 18
JO - BMC Pediatrics [E]
JF - BMC Pediatrics [E]
IS - 1
M1 - 84
ER -